Alzheimer's disease: overview, causes, symptoms, treatment, and history

Pathology

At the microscopic level, Alzheimer's disease is associated with two characteristic changes: extracellular deposits of beta-amyloid protein known as amyloid plaques, and abnormal intracellular accumulations of tau protein that form neurofibrillary tangles. These changes are linked to progressive loss of neurons and synapses, most noticeably in the hippocampus and cortical regions important for memory and language. Vascular disease, inflammation and other molecular processes also contribute to neuronal dysfunction and symptom progression.

Causes and risk factors

The exact cause of Alzheimer's remains incompletely understood; it is best viewed as a multifactorial disorder. Risk is influenced by age, genetics and environmental or lifestyle factors. Rare inherited mutations in APP, PSEN1 and PSEN2 can cause early-onset familial forms, while variation in the APOE gene, in particular the e4 allele, increases the risk of later-onset disease. Other contributions include cardiovascular health, history of head injury, diabetes, smoking and insufficient physical or cognitive activity. For general risk information see risk factor guidance.

Symptoms and clinical course

Early symptoms commonly include difficulty remembering recent events, repeating questions, trouble finding words and reduced ability to learn new information. As the disease progresses, people may develop disorientation, impaired judgment, mood and behavior changes, language difficulties and loss of the ability to manage personal care. The rate of decline varies between individuals. Some develop additional neurological signs such as movement problems or hallucinations when other pathologies coexist.

Diagnosis

Diagnosis is primarily clinical and relies on history, cognitive testing and neurologic examination. Structural imaging (MRI, CT) helps rule out other causes such as stroke or mass lesions; molecular imaging (FDG-PET, amyloid and tau PET) and cerebrospinal fluid tests can provide biomarker evidence that supports the diagnosis in selected cases. Accurate diagnosis also involves assessing functional impact and excluding reversible contributors such as medication effects, metabolic disturbances or depression.

Treatment and management

There is currently no cure for Alzheimer's disease. Available medications—cholinesterase inhibitors and NMDA receptor antagonists—may offer modest symptomatic benefits for some individuals. Research into disease-modifying therapies that target amyloid, tau and other pathways is active; some immunotherapies and novel agents have undergone clinical trials with varied results. Comprehensive care emphasizes safety, symptom management, caregiver support and planning for progressive needs.

Nonpharmacological strategies play a major role: structured routines, cognitive stimulation, physical activity, management of sleep and behavioral symptoms, and support for daily living can improve quality of life. Practical prevention and risk-reduction measures that benefit brain and cardiovascular health include regular exercise, a balanced diet, social engagement and control of blood pressure and diabetes; see prevention resources for accessible guidance.

Epidemiology and impact

Alzheimer's disease affects millions worldwide and is a leading cause of disability and dependency in older people. Prevalence rises with age, and the condition places long-term demands on families, caregivers and health systems. Public health efforts aim to improve early detection, expand support services and invest in research to discover treatments that can alter disease progression rather than only relieve symptoms.

Caregiving and support

Care for people with Alzheimer’s often requires a multidisciplinary approach involving primary care, neurology, psychiatry, social work and allied health professionals. Caregiver education, respite services and community resources are essential to maintain safety and quality of life. Legal and financial planning early after diagnosis helps families make future arrangements for decision-making and care.

History

The disease was first described by the German psychiatrist and neuropathologist Alois Alzheimer after he examined the clinical course and brain tissue of a patient, Auguste Deter, in 1906. His observations of clinical decline together with distinctive microscopic findings—neuritic plaques and neurofibrillary tangles—formed the foundation for understanding the disorder. The eponym "Alzheimer's disease" entered medical use shortly thereafter and has guided more than a century of research and clinical care.

Research directions

Contemporary research spans basic science, biomarker development, clinical trials of disease-modifying therapies and implementation studies to improve diagnosis and care delivery. Investigations explore how amyloid, tau, inflammation, vascular factors and lifestyle interact over decades to produce clinical symptoms. Early detection and interventions in preclinical stages are of particular interest because they may offer the best opportunity to slow or prevent symptomatic disease.

For introductory overviews and practical information for patients, families and caregivers, consult reputable medical organizations and specialist advocacy groups that provide accessible, evidence-based materials. Clinical teams can also advise on local services, clinical trials and supports tailored to individual needs.

Further reading and resources are available from medical libraries and dementia support organizations; for general background on brain disorders see information on dementia and for clinical care pathways consult professional guidance at clinical resources.